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ABSTRACT: Rapamycin loaded polycaprolactone nanoparticles (RAPA-PCL NPs) with a polydispersity index of 
0.006−0.073 were fabricated by anti-solvent precipitation combined with micromixing using a ringed stainless steel mem-
brane with 10-µm diameter laser-drilled pores. The organic phase composed of 6 g L−1 of PCL and 0.6−3.0 g L-1 of RAPA in 
acetone was injected through the membrane at 140 L m−2 h−1 into 0.2 wt% aqueous polyvinyl alcohol solution stirred at 
1300 rpm, resulting in a Z-average mean of 189−218 nm, a drug encapsulation efficiency of 98.8−98.9 % and a drug loading 
in the NPs of 9−33 %. The encapsulation of RAPA was confirmed by UV‐Vis spectroscopy, XRD, DSC, and ATR-FTIR. The 
disappearance of sharp characteristic peaks of crystalline RAPA in the XRD pattern of RAPA-PCL NPs revealed that the 
drug was molecularly dispersed in the polymer matrix or RAPA and PCL were present in individual amorphous domains. 
The rate of drug release in pure water was negligible due to low aqueous solubility of RAPA. RAPA-PCL NPs released 
more than 91 % of their drug cargo after 2.5 h in the release medium composed of 0.78−1.5 M of the hydrotropic agent 
N,N-diethylnicotinamide, 10 vol% of ethanol, and 2 vol% of Tween 20 in phosphate buffered saline. The dissolution of 
RAPA was slower when the drug was embedded in the PCL matrix of the NPs than dispersed in the form of pure RAPA 
nanocrystals. 
Introduction 
Rapid progress in nanomedicine has led to the devel-
opment of new drug delivery strategies for poorly water-
soluble drugs that can overcome their instability and poor 
bioavailability.1 Nanovehicles such as micelles, liposomes, 
dendrimers, quantum dots, carbon nanotubes, nanogels, 
polymeric nanospheres, solid lipid nanoparticles (NPs), 
and inorganic NPs offer increased longevity in the blood, 
enhanced intracellular penetration, site-specific targeting, 
in vivo visualization, and stimuli responsiveness.2,3 Poly-
meric NPs composed of poly(lactide-co-glycolide) 
(PLGA), poly(ᴅ,ʟ-lactide) (PDLLA), poly(ɛ-caprolactone) 
(PCL), and poly(alkyl cyanoacrylates) (PACs) are especial-
ly popular due to their controlled/sustained release prop-
erties, biocompatibility (non-toxic, non-immunogenic, 
and non-inflammatory properties), and applicability to 
many water insoluble drugs.4 Polymeric NPs can be pre-
pared by antisolvent precipitation, which is less energy 
demanding and more facile method than emulsion-
solvent evaporation and applicable without any additives 
in the aqueous phase.5–7  
Rapamycin (RAPA) or sirolimus is a carboxylic lac-
tone-lactam macrolide with antifungal, antitumor, anti-
inflammatory, and immunosuppressive properties, first 
isolated in 1975 from Streptomyces hygroscopicus. 8 Clini-
cal applications of RAPA for breast cancer therapy and 
prevention of restenosis after coronary stent placement 
was impeded by its poor solubility in water (2.6 μg⋅mL-1 at 
25 °C), low bioavailability, dose-limiting toxicity,9 and low 
stability in plasma and low- and neutral-pH buffers with a 
half-life of less than 10 h at 37 °C.8 To improve oral bioa-
vailability of RAPA, various biodegradable polymeric NPs 
with hydrophobic cores have been developed to solubilise 
RAPA and protect it against degradation after administra-
tion. RAPA-loaded PLGA, PCL-poly(ethylene glycol) 
(PEG)-PCL, PDLLA, poly(ethylene oxide) (PEO)-PLGA, 
and mPEG-b-PLA NPs were prepared using a modified 
nanoprecipitation technique,10 emulsion-solvent evapora-
tion method, 9,11–14 and the salting-out method.15 RAPA-
loaded chitosan/PLA NPs have been prepared by ultra-
sonic-assisted nanoprecipitation,16 but the process does 
not lead to narrow particle size distribution.  
 Control over the size of drug-loaded NPs is critically 
important to avoid particle uptake by the reticuloendo-
thelial system and maximise their accumulation in tu-
mour sites by exploiting the enhanced retention and 
permeability (EPR) effect. The optimal size of NPs for 
achieving the EPR effect depends on the tumour type, 
location and size, and the maximum NP size is usually 
380–780 nm.17 Size-tuneable NPs can be prepared by na-
noprecipitation/micromixing using microporous mem-
brane18,19 or microfluidic channels.20,21  
In membrane micromixing, the organic phase is intro-
duced into the aqueous phase through a microporous 
membrane under controlled injection rate and shear on 
the membrane/aqueous phase interface. Here, the role of 
membrane is to uniformly split the organic phase stream 
into numerous microstreams, allowing for more uniform 
mixing conditions compared to direct injection through a 
single injection point, e.g. via a hypodermic needle. 
Membranes commonly used in this process are composed 
of a random network of irregular pores with a wide distri-
bution of pore sizes, such as ceramic,22 polymeric hollow 
fibre,23 and Shirasu Porous Glass24 membrane. These 
membranes contain tortuous and interconnected pores, 
which make them difficult to clean, and exhibit high flow 
resistance due to significant thickness. Recently, isopo-
rous microengineered membranes with ordered pore ar-
rays have been used to prepare emulsions25 and mi-
cro/nano-particles.26,27 Such membranes have a low flow 
resistance and low tendency for fouling, due to their small 
thickness and non-interconnected, straight-through 
pores.28 Microengineered membrane was mainly used in a 
simple stirred cell, but scalable continuous systems have 
also been developed, based on pulsed back-and-forward 
cross flow29 and oscillating membrane with either upward 
and downward30 or clockwise and counterclockwise31 mo-
tion.  
In this work, novel RAPA-loaded PCL NPs (hereafter 
abbreviated as RAPA-PCL NPs) with a narrow size distri-
bution have been facilely produced by antisolvent precipi-
tation using ringed stainless steel (SS) membrane fabri-
cated by pulsed laser micromachining. This fabrication 
process leads to cylindrical pores that are less prone to 
fouling and provide more efficient mixing than funnel-
shaped pores of electroformed nickel membrane.32 The 
main objective of this  work were to investigate the effect 
of incorporation of RAPA in the polymer matrix on the 
physicochemical properties of the produced NPs and to 
study the encapsulation efficiency of RAPA inside the NPs 
and their in vitro drug release behavior in different re-
lease media. PCL is a FDA-approved biodegradable drug 
carrier, selected due to its suitability for the encapsulation 
of poorly water-soluble drugs and its negligible tendency 
to generate an acidic environment during degradation, 
which can lead to inflammatory reactions in the body.33,34  
Materials and Methods 
Materials. Poly(ε-caprolactone) (PCL, Mw = 14,000 
kDa with a glass transition temperature of 60 oC), tetra-
hydrofuran (THF, HPLC grade, purity ≥ 99.9 %), and pol-
yvinyl alcohol (PVA, Mw = 13−23 kDa, 87-89 % hydrolysed) 
were purchased from Sigma-Aldrich (Dorset, UK). PVA 
was used as a water soluble stabiliser to prevent agglom-
eration, coalescence and imperfect surface formation of 
the NPs. Acetone, (Ace, HPLC grade, purity ≥ 99.8 %), 
acetonitrile (HPLC grade, purity ≥ 99.9 %), methanol 
(HPLC grade, purity ≥ 99.8 %), acetic acid (HPLC grade, 
purity ≥ 99.7 %), and N,N-diethylnicotinamide (DENA,  
97 %, Acros Organics BVBA) were purchased from Fisher 
Scientific Ltd (Loughborough, UK). Rapamycin (RAPA, 
sirolimus, purity ≥ 99 %) was provided by Chunghwa 
Chemical Synthesis & Biotech Co. Ltd. (New Taipei City, 
Taiwan). All chemicals were of analytical grade. For 
RAPA-PCL NPs, the organic phase was prepared by dis-
solving 0.6−3.0 g L-1 of RAPA and 6 g L-1 of PCL in acetone. 
For production of RAPA nanocrystals, the organic phase 
was composed of 0.3 wt% RAPA in acetone, whilst for 
blank PCL NPs the organic phase was prepared by dis-
solving 1 g L-1 of PCL in THF or acetone. In all experi-
ments, the aqueous phase was 0.2 wt% PVA solution pre-
pared in Milli-Q water.  
Membrane and membrane module. The stirred cell 
used in this work was equipped with a flat SS membrane 
placed under a paddle blade stirrer, as shown in Figure 1a. 
Both the cell device and membrane were supplied by Mi-
cropore Technologies Ltd (Redcar, UK). The membrane 
had 6,912 pores with a diameter of 10 μm fabricated by 
laser drilling within an annular region with a surface area 
of 2.76 cm2, bounded by two concentric circles of radii r1 = 
9 mm and r2 = 13 mm. The rotation speed of 1,300 rpm was 
used in all runs, which created an average shear stress of 
13 Pa in the active (annular) region on the membrane sur-
face. The micrograph of the membrane surface in Figure 
1b shows a square pore array with a pitch of 200 μm.  
Preparation of RAPA-PCL NPs. The cell was filled 
with 60 mL of the aqueous phase and the stirrer speed 
was adjusted at 1,300 rpm. The organic phase was intro-
duced at 0.65 mL min-1 using a Cole-Parmer model 230 
VAC syringe pump to achieve a transmembrane flux of 
140 L m-2 h-1. Each experiment was run until 6 mL of the 
organic phase was injected and an aqueous-to-organic 
volumetric ratio reached 10, which took 9.2 min. The 
aqueous phase turned cloudy as soon as the organic phase 
was brought in contact with the aqueous phase, due to 
the formation of NPs that caused ambient light scattering 
as a result of different refractive index of water (1.33) and 
PCL (1.47). Once the desired amount of organic phase had 
passed through the membrane, both the pump and stirrer 
were switched off and the nanosuspension was collected 
for further analyses. Figure 1b depicts a solvent displace-
ment mechanism of NPs formation, characterised by a 
rapid exchange of water and organic solvent between the 
two phases. The organic solvent was evaporated from the 
nanosuspension in a vacuum oven (Fistreem International 
Ltd, Loughborough, UK) at room temperature under an 
absolute pressure below 10 Torr until the smell of organic 
solvent had completely disappeared (∼30 min). Every ex-
periment was carried out at least three times. 
 After each run, the membrane was rinsed with Mili-Q 
water and sonicated in acetone for 30 min using a Fisher 
Scientific, Model FB 15046, ultrasonic bath. The mem-
brane was then rinsed with Milli-Q water and washed 
with fresh Milli-Q water in the ultrasonic bath for 5 min.  
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Figure 1. (a) A schematic diagram of the dispersion cell device with a micrograph of a 10-μm ringed SS membrane; (b) Permea-
tion of the organic phase through the membrane and rapid solvent displacement at the interface between the finely dispersed 
organic phase droplets and the aqueous phase, leading to the precipitation of PCL and formation of RAPA-PCL NPs.  
 
Determination of encapsulation efficiency and 
drug loading. After complete solvent evaporation, the 
nanosuspension was ultracentrifuged (Heraeus Labofuge 
400R centrifuge, Thermo Scientific) at 15,000 rpm (23,000 
g) for 1 h. The supernatant containing the dissolved free 
drug was separated from the sediment and analysed by an 
established Reverse phase High Performance Liquid 
Chromatographic (RP-HPLC) method. Briefly, 20 μL of 
each sample was injected in a Symmetry® C-8 column (4.6 
× 50 mm, 3.5 μm, Waters, UK) eluted with methanol/1 % 
(v/v) acetic acid in deionised water (75/25 v %) at a 
flowrate of 1.0 mL min-1. A LC-10Avp Shimadzu UV-VIS 
detector was used to detect RAPA at 278 nm and ambient 
temperature. The concentration of RAPA in the sample 
was determined from a calibration curve constructed us-
ing standard RAPA solutions prepared in acetonitrile. The 
drug entrapment efficiency (E.E.) was calculated from eq. 
(1): 
 
%)]/M(M[%E.E. TR 1001 ×−=                                     (1) 
where MR is the mass of RAPA in the supernatant and 
MT is the total mass of RAPA in the sample.
11,14,16 The drug 
loading (D.L.) was calculated from:  
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where MNP is the total mass of NPs in the sample.
35,36 
The analyses were carried out in triplicates and the results 
were expressed as the mean ± SD (n = 3). 
Characterisation of the prepared NPs. Particle size 
analysis. The NPs size distribution was determined by 
Dynamic Light Scattering (DLS) using a DelsaTM Nano 
HC Particle Analyser (Beckman Coulter, High Wycombe, 
UK), which measures the fluctuations in scattered light 
intensity as a function of time.37 Smaller NPs move faster 
than larger NPs and therefore, the timescale of intensity 
fluctuations is shorter for smaller NPs. A solvent-free 
nanosuspension was transferred into a 4 mL disposable 
cuvette which was then placed into the instrument. The 
data acquisition time was 120 s for each run and the 
measurements were repeated thrice at 25 oC and 165o 
scattering angle using CONTIN and Cumulant fitting al-
gorithms. The Cumulant algorithm provides the z-average 
size, which is the harmonic intensity averaged particle 
diameter and the polydispersity index (PDI), which is a 
dimensionless measure of the broadness of the size distri-
bution. The CONTIN algorithm was developed by 
Provencher et al. and imparts average peak diameter val-
ues from intensity size distribution.38  
Transmission Electron Microscopy (TEM). RAPA-PCL 
NPs, blank NPs and RAPA nanocrystals were observed by 
JEOL JEM-2000FX analytical TEM operated at an acceler-
ating voltage of 200 kV and fitted with an Oxford Instru-
ments Inca EDX system. A drop of the free organic sol-
vent sample was deposited onto a carbon-coated copper 
mesh and left to dry before observation. The mesh was 
coated by dipping it into a suspension of carbon particles 
in deionised water.  
Differential Scanning Calorimetry (DSC). The interac-
tions between different ingredients in the synthesised 
NPs were estimated using a TA Instruments Model Q10 
calorimeter. The samples (pure RAPA, pure PCL, blank 
PCL NPs, a physical mixture of blank PCL NPs and RAPA, 
and RAPA-PCL NPs), weighting 5 mg each, were hermeti-
cally sealed in separate aluminium pans. The sample pans 
were then heated from 30 to 220 °C at a rate of 10 °C min-1 
and the DSC profiles were compared with an empty pan. 
Dry nitrogen at 10 mL min-1 was used as the purge gas. 
RAPA-PCL NPs and blank PCL NPs were prepared by 
freeze-drying the sediment after centrifugation in a freeze 
dryer (Edwards, type EF4 Modulyo). Triple runs were car-
ried out on each sample to check reproducibility. 
X-Ray Diffractometry (XRD). XRD patterns of pure 
RAPA, pure PCL, blank PLC NPs, a physical mixture of 
blank PCL NPs and RAPA, and RAPA-PCL NPs were rec-
orded using a Bruker D8 diffractometer by exposing sam-
ples to CuKa radiation (40 kV, 20 mA) over the 2θ range 
from 5o to 50o, with a step size of 0.02o, an acquisition 
time per step of 5 s and a scanning speed of 0.5° min-1. The 
samples were prepared by injection moulding under ni-
trogen at 100 °C and transferred at ambient temperature 
to a circular mould with a diameter of 20 mm and a 
thickness of 1 mm. Triple runs were carried out on each 
sample to check reproducibility. 
Attenuated Total Reflection-Fourier Transform Infrared 
(ATR-FTIR) Spectroscopy. ATR-FTIR was performed to 
detect the presence of RAPA in the polymer matrix and 
investigate possible interactions between RAPA and the 
host polymer. The IR spectra were recorded in the range 
of 4000−400 cm-1 using a Thermo Scientific Nicolet iS50 
ATR spectrometer with a monolithic diamond crystal. 2−3 
mg of the pulverised sample was placed onto the Univer-
sal diamond ATR top-plate and the spectrum was ac-
quired within 32 s. Triple runs were carried out on each 
sample to check reproducibility. 
In vitro drug release studies. In vitro dissolution testing 
of poorly water-soluble drug formulations pose significant 
problems, because the extent of drug release is often too 
low and the rate of release is too slow for a practical test. 
In this study, the enhancement of the aqueous solubility 
of RAPA has been achieved by facilitated hydrotropy.39 
Hydrotropy is a collective molecular phenomenon associ-
ated with an increase in the aqueous solubility of a poorly 
water-soluble compound by addition of a relatively large 
amount of a second solute, i.e. a hydrotrope.40 The hydro-
tropic activity of a hydrotrope can be enhanced by adding 
water miscible cosolvent(s), which is known as the facili-
tated hydrotropy. In this work, N,N-diethylnicotinamide 
(DENA) was used as a hydrotropic agent and its solubilis-
ing effect was enhanced by adding ethanol and Tween 20 
(polysorbate 20) in the dissolution medium. The RAPA 
release profiles have been assessed using 0.3 wt% RAPA-
PCL NPs and the dissolution/release medium was pre-
pared by mixing 10 vol% of pure (200 proof) ethanol, 10 
vol% of 20 % Tween 20, 25.9 vol% of aqueous DENA solu-
tion (5.8 M or 3 M), 44.1 vol% of Milli-Q water, and 10 
vol% of 10x phosphate buffered saline (PBS). A known 
amount of lyophilised sample (5 mg) was placed in a cen-
trifuge tube and dissolved in 5 mL of the dissolution me-
dium. The tube was then incubated in a shaking bath at 
50 rpm and 37 °C to mimic the human blood stream con-
ditions.41 At predetermined time intervals, the test tube 
was taken out of the shaker and centrifuged at 15,000 rpm 
for 30 min at −4 oC. The supernatant was removed and 
the amount of RAPA released was quantified by RP-HPLC 
method as described above. The volume sampled was 
replenished with fresh medium to keep the total volume 
of the release medium constant. All experiments were run 
in triplicate and the results were expressed as a mean val-
ue ± S.D. 
Results and Discussion 
Effect of organic solvent and organic/aqueous ra-
tio. The selection of suitable organic solvent is a crucial 
initial step that should be taken in the design of the na-
noprecipitation process. The chosen solvent should be 
able to dissolve the drug and polymer and should be mis-
cible with water. In this series of experiments, blank PCL 
NPs were prepared using two different organic solvents, 
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THF and acetone, and in each case five aqueous-to organ-
ic volumetric ratios have been tested. The z-average mean 
decreased with increasing the aqueous-to-organic volu-
metric ratio, as shown in Figure 2. The same trend was 
observed for itraconazole and ZnO NPs prepared via SPG 
membrane,42,43 and liposomes and micelles produced us-
ing nickel membrane.27,44,45. The size of NPs formed by 
anti-solvent precipitation is a result of the relative rates of 
nucleation, particle growth, and agglomeration. The fast-
er removal of solvent at higher Vaq/Vor values led to higher 
supersaturation levels, which promoted nucleation over 
particle growth and resulted in smaller NPs. In addition, 
agglomerates are less likely to form in more diluted sus-
pensions, because they can only form when NPs collide 
with each other and the collision frequency of NPs is pro-
portional to the second power of their number density.  
The Z-average mean was consistently smaller when 
the NPs were formed using THF as compared to acetone. 
The solvent-PCL distance in the “2δd−δp−δh” solubility 
space is equal to 1.08 and 6.53 for THF and acetone, re-
spectively,20 which means that PCL is more soluble in 
THF than acetone. Thus, compared to acetone, THF must 
be diluted with water to a greater extent for PCL to begin 
to precipitate, which means that the growing NPs are less 
likely to agglomerate. The same type of behaviour with 
smaller NPs formed using THF than acetone was observed 
for fluconazole-loaded polymeric micelles produced by 
membrane and microfluidic nanoprecipitation.46 Alt-
hough PCL NPs are smaller in the presence of THF, in 
subsequent experiments RAPA-PCL NPs will be formed 
using acetone, because RAPA is sparingly soluble in THF 
and the difference in size between the NPs formed using 
acetone and THF is only 3-8 %. To obtain the smallest 
possible NPs size, the ratio Vaq/Vor will be kept at 10. 
 
Figure 2. The Z-average size of blank PCL NPs produced 
using two different organic solvents (THF and acetone) at 
different aqueous/organic phase volumetric ratios.  
 
Drug encapsulation efficiency and drug loading. 
RAPA-PCL NPs were larger than blank PCL NPs formed 
under the same conditions and their size increased from 
189 ± 4 nm to 218 ± 5 nm with increasing the 
drug/excipient ratio in the organic phase from 0.1 to 0.5 
(Table 1). A size uniformity of the NPs deteriorated with 
an increase in the drug/excipient ratio, as revealed by an 
increase in PDI from 0.006 to 0.073. It is worth mention-
ing that PDI values smaller than 0.05 are rarely seen other 
than with highly monodispersed standards. The encapsu-
lation efficiency of RAPA was ≥ 98.8 %, due to very low 
aqueous solubility of RAPA and strong hydrophobic in-
teractions between RAPA and PCL. Based on RAPA solu-
bility in water of 0.0026 mg⋅mL-1 at 25 °C, the maximum 
amount of RAPA that could be dissolved was 0.156 mg per 
batch and the amount of RAPA added in the organic 
phase was 3.6−18 mg per batch, which means that the 
maximum loss of RAPA due to its dissolution was   
0.9−4.3 %. However, the RAPA solubility in the aqueous 
phase was greater than 0.0026 mg⋅mL-1 due to the pres-
ence of acetone diffused from the organic phase. The 
RAPA loading in the NPs increased from 9.0 wt% to 33.0 
wt% when a RAPA/PCL mass ratio in the organic phase 
increased from 0.1 to 0.5. The maximum theoretical drug 
loading corresponding to these drug-excipient ratios was 
9.1 and 33.3 %, which nearly perfectly matches experi-
mental values and proves that almost all RAPA was en-
trapped in the NPs. The similar trends were observed by 
Zhang et al. who reported an increase in the particle size 
(170 to 180 nm), encapsulation efficiency (84.1 to 99.7 %) 
and drug loading (5.03 to 14.91 %) when a RAPA/polymer 
ratio in the organic phase increased from 5 to 15 %.13  
 
Table 1: The effect of RAPA-to-PCL mass ratio in the 
organic phase on the average particle size, Zave, drug 
encapsulation efficiency, E.E., and drug loading, D.L.. 
The organic phase was prepared by dissolving RAPA 
and 6 g L-1 of PCL in acetone and Vaq/Vor = 10.  
RAPA/PCL 
mass ratio in 
organic 
phase 
Volumetric ratio, Vaq/Vor = 10 
E.E. 
(%) 
D.L. 
(%) 
Average 
size of  
NPs, Zave 
(nm) 
Polydispersity 
index (PDI) 
0.1 98.79 8.98 189 ± 4 0.006 ± 0.025 
0.2 98.80 16.47 195 ± 4 0.040 ± 0.031 
0.3 98.92 22.83 198 ± 7 0.030 ± 0.024 
0.4 98.91 28.26 204 ± 1 0.066 ± 0.035 
0.5 98.93 32.98 218 ± 5 0.073 ± 0.023 
* Note: Each analysis was repeated three times (n = 3) and 
the average particle sizes were determined. The error bars 
are standard deviations. 
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Characterisation of the NPs. TEM analysis of the 
NPs. TEM micrographs shown in Figure 3 revealed that 
blank PCL and RAPA-PCL NPs were uniform discrete 
nanospheres. RAPA-PCL NPs were larger than blank PCL 
NPs, probably because RAPA was embedded or solubil-
ised in the PCL matrix of the NPs, which is consistent 
with the results in Table 1. RAPA nanocrystals (NCs) were 
of irregular shape and bigger than RAPA-PCL NPs due to 
aggregation of RAPA nanocrystallites in the absence of 
PCL host. No free crystals were found in the sample of 
RAPA-PCL NPs. 
 
(c)
500 nm
200 nm
(a)
500 nm
200 nm
500 nm
(b)
200 nm
 
Figure 3. TEM images of the NPs prepared under identical 
experimental conditions: (a) blank PCL NPs; (b) RAPA-PCL 
NPs; and (c) pure RAPA nanocrystals without PCL host. 
RAPA-PCL NPs were prepared using the drug-to-excipient 
mass ratio in the organic phase of 0.4. 
 
TEM images in Figure 3 are well correlated with the 
intensity size distributions of the NPs shown in Figure 4. 
Blank PCL and RAPA-PCL NPs were very uniform in size 
and smaller than RAPA NCs due to the suppression of 
crystal growth by the host polymer. RAPA NCs had a 
broader size distribution due to stochastic nature of the 
agglomeration process and the average particle size was 
larger than 500 nm. These results indicate the importance 
of drug entrapment within a polymer host for obtaining 
the NPs smaller than 250 nm and the capability of ringed 
stainless steel membrane with laser-drilled pores to gen-
erate nearly monodispersed NPs.  
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Figure 4. The intensity size distributions of blank PCL NPs, 
RAPA-PCL NPs, and RAPA nanocrystals produced under 
identical experimental conditions (Vaq/Vor = 10, transmem-
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brane flux = 140 Lm-2h-1, stirrer speed = 1300 rpm). The for-
mulations are indicated in section 2.1. 
 
XRD analysis. XRD analysis was used to determine the 
degree of PCL crystallinity in the NPs, i.e. if the encapsu-
lated drug is mainly in crystalline form or molecularly 
dispersed. It is important because different physical states 
of the drug within polymer network exhibit different stor-
age stability, solubility, dissolution rate, and bioavailabil-
ity, which may significantly affect therapeutic effects of 
the drug. As can be seen in Figure 5a, the XRD pattern 1 of 
pure crystalline RAPA shows a multitudes of high-
intensity peaks at 7.2°, 9.9°, 10.3°, 11.1°, 12.5°, 14.5°, 15.3°, 
15.5°, 16.2°, 20.0°, 20.4°, 21.8° and 23.5°. The diffraction 
pattern 2 of pure PCL shows two peaks at 2θ = 21.4° and 
23.8°, corresponding to the (110) and (200) crystallograph-
ic planes of semi-crystalline PCL. Similar XRD results for 
pure RAPA and PCL were obtained by Kim et al.8 and Yeo 
et al.47, respectively. In the XRD pattern 3 of blank PCL 
NPs, the two characteristic peaks of PCL were shifted 
leftward and were less intense than in the XRD spectrum 
of pure PCL. The polymer crystallinity was reduced from 
68.9 % in the raw PCL powder to 67.1 % in the NPs, due to 
rapid polymer precipitation and a lack of time for the pol-
ymer chains to arrange themselves in an ordered manner 
before solidification.48 
 
Figure 5. (a) X-ray diffractograms; and (b) DSC ther-
mograms of: 1- pure RAPA; 2- pure PCL; 3-blank PCL NPs; 
4- physical mixture of blank PCL NPs and RAPA; and 5- 
RAPA-PCL NPs.  
 
In the XRD pattern of the physical mixture of blank 
PCL NPs and pure RAPA, specific peaks of both blank 
PCL NPs and pure RAPA were observed, suggesting that 
RAPA was in the crystalline state and did not undergo 
molecular interactions with blank PCL NPs. In the spec-
trum 5 of RAPA-PCL NPs, only the PCL peaks at 21.4° and 
23.8° were detected, while the characteristic peaks of 
RAPA disappeared. It indicates that the encapsulated 
drug was either present in the form of a molecular disper-
sion in the polymer, i.e. the drug and polymer were ho-
mogeneously mixed at the molecular level, or RAPA was 
present in the form of amorphous domains dispersed in 
the polymer matrix.49 Compared to the crystalline state, 
amorphous drug exhibits greater dissolution rate and 
greater bioavailability, but also greater chemical reactivity 
and tendency to revert back to energetically favoured 
crystalline state. The degree of crystallinity was reduced 
exo
endo
Tm = 60 oC
Tm = 183 oC
Tm = 197 oC
(a)
(b)
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from 78.9 % for pure RAPA sample to 71.3 % for the phys-
ical mixture of pure RAPA and blank PCL NPs to 63.7 % 
for RAPA-PCL NPs.  
DSC analysis. DSC is a thermodynamic tool used in 
the pharmacology to measure phase transitions in materi-
als as a function of time and temperature as well as to 
quantify an amorphous or crystalline phase in NPs and 
possible interactions between the drug and excipient.50 
The DSC profiles of pure RAPA, pure PCL, blank PCL 
NPs, mixture of pure RAPA and blank PCL NPs, and 
RAPA-PCL NPs are shown in Figure 5b. Pure crystalline 
RAPA exhibited two endothermic peaks at 183 °C and 197 
°C, corresponding to the melting points of two different 
crystalline forms of the drug.51 Pure PCL polymer exhibit-
ed an endothermic peak at 60 °C, corresponding to its 
melting point.52  
An endothermic peak in blank PCL NPs was shifted to 
∼52 °C and more diffuse, revealing the reduced crystallini-
ty of PCL after precipitation. Two endothermic peaks cor-
responding to the melting points of PCL and RAPA were 
detected in the physical mixture of pure RAPA and blank 
PCL NPs. A shallow RAPA peak between 180 and 200 °C 
can be attributed to the low proportion of the drug in the 
mixture. A PCL peak of RAPA-PCL NPs occurred at ∼50 
°C indicating that the polymer chains were more disor-
dered in the presence of RAPA in the polymer matrix than 
in blank PCL NPs. The absence of RAPA peak in RAPA-
PCL NPs confirmed our previous assumption that the 
drug did not form crystalline domains in the polymer. 
Similar observations were reported by Zhang et al.13 and 
Kim et al. 8.  
ATR-FTIR spectroscopy. FTIR analysis was used to in-
vestigate chemical integrity of RAPA and PCL during the 
nanoprecipitation process.9 The FTIR spectra of different 
samples are shown in Figure 6. Characteristic bands in 
pure RAPA appeared at 3418 cm−1, due to O–H stretching 
vibrations, at 2875 and 2932 cm−1 due to C–H stretching 
vibrations, and at 1718 cm−1 due to C=O stretching. Be-
sides, the peak at 1377 cm−1 was due to ≡CH bending and 
the peaks at 1635 cm−1 and 995 cm−1 could be assigned to 
the existence of double bonds: the peak at 1635 cm−1 was 
due to C=C stretching and the peak at 995 cm−1 was due 
to =C−H bending.  
The two peaks in the pure PCL spectrum at 2942 cm−1 
and 2867 cm−1 were due to C–H stretching in the hydro-
carbon chains of PCL and the strongest peak at ∼1720 cm−1 
was due to the C=O stretching in the ester groups. The 
strong peak at 1181 cm−1 could be assigned to C–O stretch-
ing of ester linkages.53 Besides, the asymmetric bending 
vibrations of methyl groups and the bending vibration of 
methylene group are located in the 1460 cm−1 region of 
pure PCL spectrum. The peaks at 3418 cm−1 and 1635 cm−1 
found in the pure RAPA spectrum are missing in the pure 
PCL spectrum, due to absence of O–H and C=C bonds, 
respectively.  
No change in the position of various bands was found 
in the spectrum of blank PCL NPs compared with that of 
pure PCL, which means that FTIR could not prove any 
change in the chemical structure of PCL as a result of dis-
solution and precipitation. New small peaks at 995 cm−1 
and 1635 cm−1 detected in the spectrum of the mixture of 
pure RAPA and blank PCL NPs were inherited from pure 
RAPA. The peak at 1635 cm−1 due to C=C stretching was 
visible in the spectrum of RAPA-PCL NPs, but it was tiny 
and unshifted. This indicates that RAPA was encapsulated 
within the NPs matrices, but has not strongly interacted 
with PCL. 
 
Figure 6. ATR-FTIR spectra of: 1- pure RAPA; 2- pure PCL; 3- 
blank PCL NPs; 4- physical mixture of RAPA and blank PCL 
NPs; and 5- RAPA-PCL NPs. 
In vitro release of RAPA from RAPA-PCL NPs. A fast 
and complete release of encapsulated drug from NPs after 
oral administration is an important desirable feature of 
pharmaceutical formulations. The amount of RAPA re-
leased from RAPA-PCL NPs and RAPA NCs is shown in 
Figure 7 with zero-time corresponding to the start of the 
incubation period. A complete dissolution of RAPA from 
NCs was achieved after 2.5 h using the dissolution mix-
ture containing 0.78 M DENA, 10 vol% ethanol, and 2 
vol% Tween 20 in PBS. After 18 h, a total of 91.3 % and 
93.8 % of the drug were released from RAPA-PCL NPs in 
0.78 M and 1.5 M DENA solution, respectively. The re-
maining amount of RAPA (6.2−8.7 %) was firmly bound 
to the polymer chains due to strong drug-polymer inter-
actions and could only be released by complete degrada-
tion of the polymer matrix. A burst release of more than 
80 % of RAPA was observed over the first 1 hour. The fast-
est release was observed from RAPA NCs due to the ab-
sence of PCL host. The Peppas empirical model54 was the 
most appropriate model to fit the release data for small 
values of time: MR/M∞ = kt
n, where MR/M∞ is the fraction 
of RAPA released at time t. The release exponent n was 
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found to range between 0.83 and 0.90, which means that 
the drug was released by non-Fickian diffusion. 
The higher amount of RAPA was released in the disso-
lution medium containing higher concentration of DENA. 
The previous research55 confirmed that DENA is as an 
efficient hydrotropic agent for accelerated release of 
paclitaxel, another poorly water-soluble drug, from bio-
degradable polymer matrices. The potential mechanisms 
of hydrotropic action of DENA are stacking complexation, 
chaotropic activity, and self-association.56 Stacking com-
plexation between the planar aromatic rings of DENA and 
RAPA occurs due to tendency of the system to minimise 
the exposure of hydrophobic molecular regions to water. 
DENA also acts as a chaotropic agent disrupting the hy-
drogen bonds between water molecules, which results in 
the higher solubility of nonpolar solutes. Finally, DENA 
can self-assemble into micelles, followed by the incorpo-
ration of RAPA into their hydrophobic cores,56 which in-
creases the solubility of RAPA. No drug release from 
RAPA-PCL NPs was detected after 18 h of incubation in 
pure water, due to poor aqueous solubility of RAPA (2.6 
μmL-1 at 25 °C).39 
 
Figure 7. The release profile of RAPA from: (a) RAPA NCs in 
0.78 M DENA solution; (b) RAPA-PCL NPs in 0.78 M DENA 
solution; (c) RAPA-PCL NPs in 1.5 M DENA solution; and (d) 
RAPA-PCL NPs in water. The dissolution medium is an 
aqueous solution containing 0.78 or 1.5 M DENA, 10 vol% of 
ethanol, 2 vol% of Tween 20, and 1X PBS. The error bars rep-
resent the standard deviations of three repeated measure-
ments (n = 3). 
Conclusions 
Polycaprolactone (PCL) NPs loaded with the immuno-
suppressive drug rapamycin (RAPA) have been facilely 
prepared by antisolvent precipitation using a ringed stain-
less steel membrane with laser drilled pores. Due to op-
timum position of the pores localised in the region of 
maximum shear, nearly monodispersed particles have 
been obtained with a polydispersity index (PDI) of 
0.006−0.073. The particle size increased with increasing 
the RAPA content in the polymer network and the drug 
encapsulation efficiency was above 98.8% in all samples. 
Drug-loaded PCL NPs were significantly smaller and more 
uniform than RAPA nanocrystals prepared under the 
same conditions but without PCL host, revealing the im-
portant role of PCL in inhibiting particle growth and ag-
glomeration during nanoprecipitation.  
The encapsulation of RAPA in the PCL matrix was 
confirmed by UV-Vis spectroscopy, XRD, DSC, and ATR-
FTIR. The disappearance of characteristic sharp peaks of 
crystalline RAPA in the XRD pattern of RAPA-PCL NPs 
revealed that the drug was molecularly dispersed in the 
polymer matrix or the drug and polymer were present in 
individual amorphous domains. When RAPA-PCL NPs 
were stored in pure water at room temperature, the re-
lease of RAPA could not be detected due to negligible 
aqueous solubility of RAPA. However, drug-loaded NPs 
released more than 91 % of their drug cargo after 2.5 h of 
incubation in the dissolution medium composed of the 
mixture of the hydrotropic agent N,N-
diethylnicotinamide, ethanol, and a non-ionic surfactant, 
Tween 20 in phosphate buffered saline. The dissolution of 
RAPA was slower when the drug was embedded in the 
PCL matrix of the NPs than present in the form of pure 
RAPA nanocrystals. The prepared NPs can be used for a 
prolonged drug release in anti-cancer and anti-restenotic 
therapies. Our future work will be focused on the in-vivo 
drug release studies in order to simulate the actual body 
conditions. The production of uniform drug nanocrystals 
will be also optimized.  
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